Dermatomyositis and polymyositis (myositis) trials in France

In France 31 Also abroad 124

20 of 31 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 3Not yet taking people in France
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
Where
Angers, Bordeaux, Caen, Lyon, Paris, Strasbourg, Toulouse
Age
18 years and over
People
270 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07789015 · EU 2026-526365-24-00
Phase 1Taking people
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
Where
Montpellier Cedex 5, Paris
Age
18 years and over
People
78 worldwide
Run by
Chugai Pharmaceutical Co. Ltd.
See details and how to join2024-511346-39-00
Phase 1Taking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Bordeaux, Montpellier, Nancy, Paris, Strasbourg Cedex 2, Toulouse Cedex 9
Age
18 years to 70 years
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
Phase 3Completed
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Where
Lyon Cedex 03, Paris, Rouen Cedex, Strasbourg Cedex
Age
18 years and over
People
240 worldwide
Run by
argenx
See details and how to joinNCT05979441 · EU 2022-502851-79-00
Phase 1Not yet taking people in France
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Montpellier, Paris
Age
18 years and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Where
Angers, Brest Cedex 2, Le Mans Cedex 9, Lille Cedex, Lyon Cedex 03, Paris, Reims Cedex, Rouen Cedex, Strasbourg Cedex 2, Toulouse Cedex 9
Age
18 years and over
People
84 worldwide
Run by
AstraZeneca AB
See details and how to join2023-504022-19-01
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Where
Angers, Brest, Le Mans, Lille, Lyon, Paris, Reims, Rouen, Strasbourg, Toulouse
Age
18 years to 75 years
People
240 worldwide
Run by
AstraZeneca
See details and how to joinNCT06455449
Phase 2Taking people
Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study
Where
Bordeaux, Bron, Le Kremlin-Bicetre, Limoges, Paris, Paris Cedex 10, Paris Cedex 13, Rennes, Rouen Cedex, Toulouse, Toulouse Cedex 9
Age
6 months to 64 years
People
40
Run by
University Hospital, Limoges
See details and how to joinNCT03582800 · EU 2024-511620-13-00
Phase 3Taking people
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Where
Lyon, Paris, Reims Cedex, Strasbourg Cedex
Age
18 years and over
People
318 worldwide
Run by
Pfizer
See details and how to joinNCT05895786 · EU 2022-502739-20-00
Phase 1Not yet taking people in France
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases
Where
Villejuif
Age
18 years to 75 years
People
6
Run by
Gustave Roussy, Cancer Campus, Grand Paris
See details and how to joinNCT07544225
Phase 1Not yet taking people in France
A Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease.
Where
Clermont-Ferrand, Créteil, Grenoble Cedex 9, Toulouse Cedex 9
Age
18 years and over
People
51 worldwide
Run by
CRISPR Therapeutics AG
See details and how to join2024-518528-54-00
Phase 2Completed
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Where
Marseille, Montpellier, Toulouse Cedex 9
Age
18 years and over
People
90 worldwide
Run by
Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00
Phase 1Active, not recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Where
Montpellier Cedex 5, Paris Cedex 13
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00
Phase 1Enrolling by invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Where
Montpellier, Paris
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06723106
Phase 1Taking people
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Where
Lille Cedex, Strasbourg Cedex 2
Age
18 years and over
People
125 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00
No phaseTaking people
Adult Autoimmune Myopathies (MAIA)
Where
Brest
Age
18 years and over
People
60
Run by
University Hospital, Brest
See details and how to joinNCT04792931
Phase 1Taking people
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Where
Bordeaux, Toulouse Cedex 9
Age
18 years to 70 years
People
44 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00
Phase 3Taking people
Baricitinib in Patients With Relapsing or naïve Dermatomyositis
Where
Amiens, Bordeaux, Brest, Clermont-Ferrand, Clermont Ferrand Cedex 1, Creteil, Dijon, Lille, Lyon Cedex 03, Marseille, Montpellier Cedex 5, Nantes, Paris, Paris Cedex 13, Pringy Cedex, Reims Cedex, Strasbourg Cedex 2
Age
18 years to 64 years
People
62
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT04972760 · EU 2024-511899-32-00
Phase 2Taking people
Ruxolitinib Treatment in Inclusion Body Myositis
Where
Angers, Bayonne, Besançon, Bordeaux, Brest, Bron, Caen, Créteil, Garches, Lille, Limoges, Marseille, Montpellier, Nancy, Nantes, Nice, Paris, Reims, Saint-Etienne, Strasbourg, Toulouse
Age
45 years and over
People
80
Run by
Assistance Publique - Hôpitaux de Paris
See details and how to joinNCT06536166
Phase 1Taking people
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Where
Paris
Age
12 years to 70 years
People
244 worldwide
Run by
Fate Therapeutics
See details and how to joinNCT06308978